Role of insulin-like growth factor 1 in drug resistance to EGFR-TKIs in non-small cell lung cancer
CSTR:
Author:
Affiliation:

Department of Oncology,Shanghai Pulmonary Hospital Tongji University School of Medical,Shanghai,Department of Oncology,Shanghai Pulmonary Hospital Tongji University School of Medical,Shanghai,Department of Oncology,Shanghai Pulmonary Hospital Tongji University School of Medical,Shanghai,Department of Oncology,Shanghai Pulmonary Hospital Tongji University School of Medical,Shanghai,Central lab,Shanghai Pulmonary Hospital Tongji University School of Medical,Shanghai,Central lab,Shanghai Pulmonary Hospital Tongji University School of Medical,Shanghai,Department of Oncology,Shanghai Pulmonary Hospital Tongji University School of Medical,Shanghai

Clc Number:

Fund Project:

Supported by Project of Shanghai Municipal Health Bureau (2010045).

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    Objective To investigate the expression of insulin-like growth factor 1 (IGF-1) in epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) resistant non-small cell lung cancer (NSCLC) cell lines and patients, and to discuss the relevant clinical significance. Methods Levels of IGF-1 were measured by ELISA kit in PC9, A549, H1975 cells and sera of EGFR-TKIs treated NSCLC patients; insulin-like growth factor-binding protein (IGFBP) expression was examined by Western blotting analysis and immunocytochemical method. Cell growth of NSCLC cells treated with gefitinib and BMS536924 (antagonist of IGF-1 receptor) was determined by MTT. The clinicopathological characteristics and survival period of 84 patients receiving EGFR-TKIs treatment were collected and their relationship with IGF-1 expression was analyzed. Results It was found that IGF-1 level in sensitive cell line PC9 was significantly higher than those in EGFR-TKIs resistant cell lines A549 and H1975 (P<0.05), while IGFBP expression was lower than those in A549 and H1975 cells. Addition of BMS536924 of different concentrations significantly promoted the inhibitory effect of gefitinib against growth of A549 and H1975 cells (P<0.05).The patients with disease progression showed higher IGF-1 expression than those without disease progression (P=0.052),while the patients with intrinsic resistance to EGFR-TKIs had significantly higher IGF-1 level than those with acquired resistance (P=0.02). The patients with IGF-1 negative expression had significantly longer survival than those with positive expression(P=0.002). Conclusion IGF-1 expression is detected in EGFR-TKIs resistant NSCLC cell lines and patients, and antagonist of IGF-1 receptor can restore the sensitivity to EGFR-TKIs. The expression of IGF-1 is also a prognostic factor of NSCLC patients.

    Reference
    Related
    Cited by
Related Videos

Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:April 13,2014
  • Revised:September 25,2014
  • Adopted:November 21,2014
  • Online: November 26,2014
  • Published:
Article QR Code